Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024

Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr

Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'

EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma

Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024